{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T11:14:33Z","timestamp":1770549273375,"version":"3.49.0"},"reference-count":193,"publisher":"Elsevier","isbn-type":[{"value":"9780443297021","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.acc.2024.04.003","type":"book-chapter","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T16:27:44Z","timestamp":1715704064000},"page":"132-171","source":"Crossref","is-referenced-by-count":4,"title":["Pleiotropic functions and clinical importance of circulating HDL-PON1 complex"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.acc.2024.04.003_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cbi.2016.05.036","article-title":"Paraoxonases-1,-2 and-3: what are their functions?","volume":"259","author":"Furlong","year":"2016","journal-title":"Chem. Biol. Interact."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1073\/pnas.2536901100","article-title":"Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization","volume":"101","author":"Aharoni","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/bs.acc.2024.04.003_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108067","article-title":"Importance of paraoxonase 1 (PON1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications of type 2 diabetes: genotypic and phenotypic evaluation","volume":"161","author":"Shokri","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/bs.acc.2024.04.003_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-405211-6.00003-6","article-title":"Paraoxonases: ancient substrate hunters and their evolving role in ischemic heart disease","volume":"59","author":"Martinelli","year":"2013","journal-title":"Adv. Clin. Chem."},{"issue":"48","key":"10.1016\/bs.acc.2024.04.003_bib5","doi-asserted-by":"crossref","first-page":"44444","DOI":"10.1074\/jbc.M105660200","article-title":"Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein","volume":"276","author":"Ng","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib6","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/01.ATV.0000059385.95664.4D","article-title":"Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress","volume":"23","author":"Rosenblat","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2024.04.003_bib7","article-title":"Paraoxonase-2 variants potentially influence insulin resistance, beta-cell function, and their interrelationships with alanine aminotransferase in type 2 diabetes","volume":"23","author":"Qujeq","year":"2018","journal-title":"J. Res. Med. Sci.: Off. J. Isfahan Univ. Med. Sci."},{"key":"10.1016\/bs.acc.2024.04.003_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.freeradbiomed.2018.04.583","article-title":"Paraoxonase 2 prevents the development of heart failure","volume":"121","author":"Li","year":"2018","journal-title":"Free. Radic. Biol. Med."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.freeradbiomed.2008.03.023","article-title":"Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues","volume":"45","author":"Marsillach","year":"2008","journal-title":"Free. Radic. Biol. Med."},{"issue":"8","key":"10.1016\/bs.acc.2024.04.003_bib10","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/01.RES.0000266976.89667.31","article-title":"Human PON3, effects beyond the HDL: clues from human PON3 transgenic mice","volume":"100","author":"Draganov","year":"2007","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2010.08.076","article-title":"The three-gene paraoxonase family: physiologic roles, actions and regulation","volume":"214","author":"Pr\u00e9court","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2024.04.003_bib12","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R3779","article-title":"Regulation of BK channel expression by Paraoxonase 3","volume":"36","author":"Shi","year":"2022","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gene.2015.04.088","article-title":"Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles","volume":"567","author":"Mackness","year":"2015","journal-title":"Gene"},{"key":"10.1016\/bs.acc.2024.04.003_bib14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cca.2014.09.016","article-title":"Paraoxonase 1 and HDL maturation","volume":"439","author":"Gugliucci","year":"2015","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1574884711666160915153433","article-title":"Pharmacological interactions of paraoxonase 1 (PON1): a HDL-bound antiatherogenic enzyme","volume":"11","author":"Mahrooz","year":"2016","journal-title":"Curr. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2004.08.039","article-title":"Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells","volume":"179","author":"Deakin","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2024.04.003_bib17","doi-asserted-by":"crossref","first-page":"11177","DOI":"10.1007\/s11033-012-2027-8","article-title":"R-carrying genotypes of serum paraoxonase (PON1) 192 polymorphism and higher activity ratio are related to susceptibility against ischemic stroke","volume":"39","author":"Mahrooz","year":"2012","journal-title":"Mol. Biol. Rep."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MOL.0b013e32833bcdc1","article-title":"Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities","volume":"21","author":"Kontush","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0022-2275(20)30115-2","article-title":"Antioxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II","volume":"43","author":"Boisfer","year":"2002","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng0996-55","article-title":"Apolipoprotein E allele\u2013specific antioxidant activity and effects on cytotoxicity by oxidative insults and \u03b2\u2013amyloid peptides","volume":"14","author":"Miyata","year":"1996","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1161\/01.ATV.21.6.1023","article-title":"Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E\u2013Deficient mice","volume":"21","author":"Ostos","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2024.04.003_bib22","doi-asserted-by":"crossref","first-page":"1065967","DOI":"10.3389\/fcvm.2023.1065967","article-title":"Paraoxonase 1 and atherosclerosis","volume":"10","author":"Durrington","year":"2023","journal-title":"Front. Cardiovasc. Med."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib23","first-page":"1","article-title":"Associations of the PON1 rs662 polymorphism with circulating oxidized low-density lipoprotein and lipid levels: a systematic review and meta-analysis","volume":"17","author":"Luo","year":"2018","journal-title":"Lipids Health Dis."},{"key":"10.1016\/bs.acc.2024.04.003_bib24","doi-asserted-by":"crossref","first-page":"E144","DOI":"10.25011\/cim.v35i3.16590","article-title":"Increased oxidized-LDL levels and arylesterase activity\/HDL ratio in ESRD patients treated with hemodialysis","author":"Mahrooz","year":"2012","journal-title":"Clin. Investig. Med."},{"key":"10.1016\/bs.acc.2024.04.003_bib25","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jacc.2009.07.006","article-title":"Cardiovascular event risk: high-density lipoprotein and paraoxonase","author":"Superko","year":"2009","journal-title":"Am. Coll. Cardiol. Found. Washington, DC"},{"key":"10.1016\/bs.acc.2024.04.003_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.trsl.2016.02.008","article-title":"Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy","volume":"173","author":"Annema","year":"2016","journal-title":"Transl. Res."},{"issue":"18","key":"10.1016\/bs.acc.2024.04.003_bib27","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.2174\/0929867326666190201142321","article-title":"Cardioprotective properties of HDL: structural and functional considerations","volume":"27","author":"Pappa","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"23","key":"10.1016\/bs.acc.2024.04.003_bib28","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1161\/CIRCULATIONAHA.120.044221","article-title":"HDL in the 21st century: a multifunctional roadmap for future HDL research","volume":"143","author":"Rohatgi","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/cvr\/cvu147","article-title":"HDL-mediated mechanisms of protection in cardiovascular disease","volume":"103","author":"Kontush","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib30","article-title":"High-density lipoproteins (HDL): novel function and therapeutic applications","volume":"1867","author":"Darabi","year":"2022","journal-title":"Biochimica et. Biophysica Acta (BBA)-Molecular Cell Biol. Lipids"},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib31","article-title":"HDL maturation and remodelling","volume":"1867","author":"Ong","year":"2022","journal-title":"Biochimica et. Biophysica Acta (BBA)-Molecular Cell Biol. Lipids"},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib32","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOL.0000000000000294","article-title":"HDLs in crises","volume":"27","author":"von Eckardstein","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/bs.acc.2024.04.003_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/bs.acc.2019.04.002","article-title":"Lipid trafficking in cardiovascular disease","volume":"92","author":"Sposito","year":"2019","journal-title":"Adv. Clin. Chem."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2009.05.034","article-title":"HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis","volume":"208","author":"Tsompanidi","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2024.04.003_bib35","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00109-005-0030-4","article-title":"Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL","volume":"84","author":"Zannis","year":"2006","journal-title":"J. Mol. Med."},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.numecd.2006.01.012","article-title":"Modified HDL: biological and physiopathological consequences","volume":"16","author":"Norata","year":"2006","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/bs.acc.2024.04.003_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/brv.12948","article-title":"Deciphering structural aspects of reverse cholesterol transport: mapping the knowns and unknowns","author":"Sacher","year":"2023","journal-title":"Biol. Rev."},{"key":"10.1016\/bs.acc.2024.04.003_bib38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.atherosclerosis.2019.04.218","article-title":"Paraoxonase-1 activities in individuals with different HDL circulating levels: implication in reverse cholesterol transport and early vascular damage","volume":"285","author":"Cervellati","year":"2019","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib39","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/HCO.0b013e32833f0382","article-title":"Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL","volume":"25","author":"Shah","year":"2010","journal-title":"Curr. Opin. Cardiol."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib40","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1373\/clinchem.2010.155333","article-title":"HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events","volume":"57","author":"Rosenson","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/bs.acc.2024.04.003_bib41","article-title":"Associations of lipoprotein subclasses with risk of all\u2010cause and cardiovascular disease mortality in individuals with type 2 diabetes: a prospective cohort study","author":"Li","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/bs.acc.2024.04.003_bib42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.athplu.2021.08.006","article-title":"Breakfast partly restores the anti-inflammatory function of high-density lipoproteins from patients with type 2 diabetes mellitus","volume":"44","author":"Lemmers","year":"2021","journal-title":"Atheroscler. Plus"},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/14789450.2018.1402680","article-title":"Quantifying HDL proteins by mass spectrometry: how many proteins are there and what are their functions?","volume":"15","author":"Shao","year":"2018","journal-title":"Expert. Rev. Proteom."},{"issue":"8","key":"10.1016\/bs.acc.2024.04.003_bib44","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/CIRCULATIONAHA.112.108753","article-title":"Altered activation of endothelial anti-and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein\u2013proteome remodeling","volume":"127","author":"Riwanto","year":"2013","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/bs.acc.2024.04.003_bib45","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2019.01.073","article-title":"Association of an HDL apolipoproteomic score with coronary atherosclerosis and cardiovascular death","volume":"73","author":"Natarajan","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/bs.acc.2024.04.003_bib46","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1161\/01.ATV.0000041405.07367.B5","article-title":"Mast cell tryptase degrades HDL and blocks its function as an acceptor of cellular cholesterol","volume":"22","author":"Lee","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/bs.acc.2024.04.003_bib47","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1172\/JCI118658","article-title":"Chymase in exocytosed rat mast cell granules effectively proteolyzes apolipoprotein AI-containing lipoproteins, so reducing the cholesterol efflux-inducing ability of serum and aortic intimal fluid","volume":"97","author":"Lindstedt","year":"1996","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib48","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.atherosclerosis.2009.07.027","article-title":"Mast cell-dependent proteolytic modification of HDL particles during anaphylactic shock in the mouse reduces their ability to induce cholesterol efflux from macrophage foam cells ex vivo","volume":"208","author":"Judstr\u00f6m","year":"2010","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib49","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1042\/bj3620627","article-title":"Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein AI at both the N-and C-termini","volume":"362","author":"Eberini","year":"2002","journal-title":"Biochem. J."},{"issue":"32","key":"10.1016\/bs.acc.2024.04.003_bib50","doi-asserted-by":"crossref","first-page":"22627","DOI":"10.1074\/jbc.274.32.22627","volume":"274","author":"Lindstedt","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib51","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1096\/fj.14-262956","article-title":"Matrix metalloproteinase 8 degrades apolipoprotein A\u2010I and reduces its cholesterol efflux capacity","volume":"29","author":"Salminen","year":"2015","journal-title":"FASEB J."},{"issue":"10","key":"10.1016\/bs.acc.2024.04.003_bib52","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","article-title":"Biological activities of HDL subpopulations and their relevance to cardiovascular disease","volume":"17","author":"Camont","year":"2011","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-017-0613-8","article-title":"The anti-inflammatory function of HDL is impaired in type 2 diabetes: role of hyperglycemia, paraoxonase-1 and low grade inflammation","volume":"16","author":"Ebtehaj","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/iub.588","article-title":"Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation","volume":"64","author":"Hine","year":"2012","journal-title":"IUBMB Life"},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib55","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1172\/JCI118345","article-title":"Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures","volume":"96","author":"Van Lenten","year":"1995","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/bs.acc.2024.04.003_bib56","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1161\/01.RES.0000146031.94850.5f","article-title":"Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential","volume":"95","author":"Ribas","year":"2004","journal-title":"Circ. Res."},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib57","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1194\/jlr.M062174","article-title":"Impact of individual acute phase serum amyloid A isoforms on HDL metabolism in mice","volume":"57","author":"Kim","year":"2016","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib58","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/1873-3468.12116","article-title":"Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks","volume":"590","author":"Frame","year":"2016","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s10020-018-0047-0","article-title":"Serum amyloid A\u2014a review","volume":"24","author":"Sack","year":"2018","journal-title":"Mol. Med."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.arcmed.2011.05.002","article-title":"Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome","volume":"42","author":"Kappelle","year":"2011","journal-title":"Arch. Med. Res."},{"key":"10.1016\/bs.acc.2024.04.003_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/481437","article-title":"Paired measurements of paraoxonase 1 and serum amyloid A as useful disease markers","volume":"2013","author":"Kotani","year":"2013","journal-title":"BioMed. Res. Int."},{"issue":"12","key":"10.1016\/bs.acc.2024.04.003_bib62","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/j.bbalip.2016.01.011","article-title":"Lipoprotein carriers of microRNAs","volume":"1861","author":"Michell","year":"2016","journal-title":"Biochimica et. Biophysica Acta (BBA)-Molecular Cell Biol. Lipids"},{"key":"10.1016\/bs.acc.2024.04.003_bib63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2019.04.227","article-title":"High-density lipoproteins induce miR-223-3p biogenesis and export from myeloid cells: role of scavenger receptor BI-mediated lipid transfer","volume":"286","author":"Torres","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/10408363.2021.1974334","article-title":"Oxidized LDL-regulated microRNAs for evaluating vascular endothelial function: molecular mechanisms and potential biomarker roles in atherosclerosis","volume":"59","author":"Kianmehr","year":"2022","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/bs.acc.2024.04.003_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6830560","article-title":"Noncoding RNA roles in pharmacogenomic responses to aspirin: new molecular mechanisms for an old drug","volume":"2021","author":"Khazeei Tabari","year":"2021","journal-title":"BioMed. Res. Int."},{"key":"10.1016\/bs.acc.2024.04.003_bib66","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2016.09.001","article-title":"HDL and microRNA therapeutics in cardiovascular disease","volume":"168","author":"Michell","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib67","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/ncomms4292","article-title":"HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells","volume":"5","author":"Tabet","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.acc.2024.04.003_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acc.2018.07.001","article-title":"Long noncoding RNAs: advances in lipid metabolism","volume":"87","author":"Zeng","year":"2018","journal-title":"Adv. Clin. Chem."},{"issue":"12","key":"10.1016\/bs.acc.2024.04.003_bib69","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1021\/acs.jproteome.5b00730","article-title":"Combined high-density lipoprotein proteomic and glycomic profiles in patients at risk for coronary artery disease","volume":"14","author":"Krishnan","year":"2015","journal-title":"J. Proteome Res."},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib70","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbalip.2019.01.005","article-title":"Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties","volume":"1864","author":"Sukhorukov","year":"2019","journal-title":"Biochimica et. Biophysica Acta (BBA)-Molecular Cell Biol. Lipids"},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib71","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/pr4012393","article-title":"Glycomic analysis of high density lipoprotein shows a highly sialylated particle","volume":"13","author":"Huang","year":"2014","journal-title":"J. Proteome Res."},{"issue":"1-2","key":"10.1016\/bs.acc.2024.04.003_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0009-8981(94)05975-X","article-title":"Reactivity of lecithin-cholesterol acyl transferase (LCAT) towards glycated high-density lipoproteins (HDL)","volume":"234","author":"Fournier","year":"1995","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib73","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0026-0495(99)90024-0","article-title":"Glycation of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity","volume":"48","author":"Rashduni","year":"1999","journal-title":"Metabolism"},{"issue":"1-2","key":"10.1016\/bs.acc.2024.04.003_bib74","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0009-8981(00)00336-3","article-title":"Diminished rate of mouse peritoneal macrophage cholesterol efflux is not related to the degree of HDL glycation in diabetes mellitus","volume":"301","author":"Passarelli","year":"2000","journal-title":"Clin. Chim. Acta"},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib75","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1194\/jlr.M200256-JLR200","article-title":"Characterization of specifically oxidized apolipoproteins in mildly oxidized high density lipoprotein","volume":"44","author":"Pankhurst","year":"2003","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib76","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.arcmed.2017.03.010","article-title":"The polymorphic variants rs3088442 and rs2292334 in the organic cation transporter 3 (OCT3) gene and susceptibility against Type 2 diabetes: role of their interaction","volume":"48","author":"Mahrooz","year":"2017","journal-title":"Arch. Med. Res."},{"key":"10.1016\/bs.acc.2024.04.003_bib77","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00125-004-1655-5","article-title":"Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia","volume":"48","author":"Nobecourt","year":"2005","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/bs.acc.2024.04.003_bib78","doi-asserted-by":"crossref","first-page":"6457","DOI":"10.1073\/pnas.88.15.6457","article-title":"High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification","volume":"88","author":"Nagano","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0891-5849(94)00170-O","article-title":"Cholesterylester hydroperoxide reducing activity associated with isolated high-and low-density lipoproteins","volume":"18","author":"Sattler","year":"1995","journal-title":"Free. Radic. Biol. Med."},{"issue":"9","key":"10.1016\/bs.acc.2024.04.003_bib80","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1172\/JCI67478","article-title":"Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex","volume":"123","author":"Huang","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib81","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.ATV.21.4.473","article-title":"Paraoxonase and atherosclerosis","volume":"21","author":"Durrington","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib82","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/1071576021000036614","article-title":"PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity","volume":"37","author":"Jaouad","year":"2003","journal-title":"Free. Radic. Res."},{"issue":"9","key":"10.1016\/bs.acc.2024.04.003_bib83","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/01.ATV.13.9.1334","article-title":"Interaction of oxidized HDLs with J774-A1 macrophages causes intracellular accumulation of unesterified cholesterol","volume":"13","author":"Musanti","year":"1993","journal-title":"Arterioscler. Thromb. J. Vasc. Biol."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0021-9150(96)05840-6","article-title":"In vitro oxidised HDL exerts a cytotoxic effect on macrophages","volume":"125","author":"Hurtado","year":"1996","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib85","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0006-291X(03)00308-5","article-title":"NF-\u03baB activation in endothelial cells treated with oxidized high-density lipoprotein","volume":"303","author":"Matsunaga","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2141.2004.05163.x","article-title":"Oxidised\u2010HDL3 induces the expression of PAI\u20101 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization","volume":"127","author":"Norata","year":"2004","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2008.11.001","article-title":"Paraoxonase 1 (PON1) status and substrate hydrolysis","volume":"235","author":"Richter","year":"2009","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib88","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nsmb767","article-title":"Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes","volume":"11","author":"Harel","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib89","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/jacs.6b10801","article-title":"Active site hydrophobicity and the convergent evolution of paraoxonase activity in structurally divergent enzymes: the case of serum paraoxonase 1","volume":"139","author":"Blaha-Nelson","year":"2017","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib90","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/10408360802610878","article-title":"The paraoxonases: role in human diseases and methodological difficulties in measurement","volume":"46","author":"Camps","year":"2009","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib91","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jcla.20490","article-title":"Naringenin is an inhibitor of human serum paraoxonase (PON1): an in vitro study","volume":"25","author":"Mahrooz","year":"2011","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/bs.acc.2024.04.003_bib92","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clinbiochem.2019.01.003","article-title":"Unexpectedly higher diazoxon hydrolysis by serum paraoxonase-1 in coronary heart disease","volume":"65","author":"Mackness","year":"2019","journal-title":"Clin. Biochem."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib93","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.3390\/jcm12031199","article-title":"Paraoxonase 1 and chronic kidney disease: a meta-analysis","volume":"12","author":"Watanabe","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/bs.acc.2024.04.003_bib94","doi-asserted-by":"crossref","DOI":"10.4103\/ijpvm.ijpvm_161_21","article-title":"Paraoxonase 1 activity is associated with interleukin-6 levels in type 2 diabetes: effects of age and gender","volume":"14","author":"Nikzad","year":"2023","journal-title":"Int. J. Preventive Med."},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib95","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/cells12050746","article-title":"Depletion of paraoxonase 1 (PON1) dysregulates mTOR, autophagy, and accelerates amyloid beta accumulation in mice","volume":"12","author":"Witucki","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib96","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1161\/ATVBAHA.112.253930","article-title":"Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk","volume":"32","author":"Tang","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/bs.acc.2024.04.003_bib97","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/bs.acc.2020.08.011","article-title":"Oxidative stress biomarkers in the preterm infant","volume":"102","author":"S\u00e1nchez-Illana","year":"2021","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/bs.acc.2024.04.003_bib98","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/B978-0-12-800094-6.00007-8","article-title":"Paraoxonases and chemokine (C\u2013C Motif) ligand-2 in noncommunicable diseases","volume":"63","author":"Camps","year":"2014","journal-title":"Adv. Clin. Chem."},{"issue":"9","key":"10.1016\/bs.acc.2024.04.003_bib99","doi-asserted-by":"crossref","first-page":"7764","DOI":"10.3390\/ijms24097764","article-title":"Proteomic exploration of paraoxonase 1 function in health and disease","volume":"24","author":"Jakubowski","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.carpath.2007.10.001","article-title":"Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia","volume":"17","author":"Ng","year":"2008","journal-title":"Cardiovasc. Pathol."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib101","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbalip.2018.12.008","article-title":"Paraoxonase 1 in endothelial cells impairs vasodilation induced by arachidonic acid lactone metabolite","volume":"1864","author":"Gilad","year":"2019","journal-title":"Biochimica et. Biophysica Acta (BBA)-Molecular Cell Biol. Lipids"},{"issue":"16","key":"10.1016\/bs.acc.2024.04.003_bib102","doi-asserted-by":"crossref","first-page":"6371","DOI":"10.1021\/bi047440d","article-title":"Structure\u2212reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase","volume":"44","author":"Khersonsky","year":"2005","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib103","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.1074\/jbc.M512595200","article-title":"The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux","volume":"281","author":"Rosenblat","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.acc.2024.04.003_bib104","first-page":"127","article-title":"Biochemistry of statins","volume":"73","author":"Egom","year":"2016"},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1515\/CCLM.2011.004","article-title":"Serum paraoxonase 1 (PON1) lactonase activity is lower in end-stage renal disease patients than in healthy control subjects and increases after hemodialysis","volume":"49","author":"Gugliucci","year":"2011","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/bs.acc.2024.04.003_bib106","first-page":"82","article-title":"Chemical biology of homocysteine thiolactone and related metabolites","volume":"55","author":"Jakubowski","year":"2011","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/bs.acc.2024.04.003_bib107","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2018.11.004","article-title":"The combined utility of myeloperoxidase (MPO) and paraoxonase 1 (PON1) as two important HDL-associated enzymes in coronary artery disease: which has a stronger predictive role?","volume":"280","author":"Variji","year":"2019","journal-title":"Atherosclerosis"},{"issue":"3-4","key":"10.1016\/bs.acc.2024.04.003_bib108","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jmb.2012.02.042","article-title":"Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1","volume":"418","author":"Ben-David","year":"2012","journal-title":"J. Mol. Biol."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib109","article-title":"Paraoxonase\u20101 (PON1) status analysis using non\u2010organophosphate substrates","volume":"1","author":"Marsillach","year":"2021","journal-title":"Curr. Protoc."},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib110","doi-asserted-by":"crossref","first-page":"7649","DOI":"10.1074\/jbc.M512594200","article-title":"The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases","volume":"281","author":"Khersonsky","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/bs.acc.2024.04.003_bib111","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1021\/bi982281h","article-title":"Identification of residues essential for human paraoxonase (PON1) arylesterase\/organophosphatase activities","volume":"38","author":"Josse","year":"1999","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib112","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1194\/jlr.P033266","article-title":"Novel common and rare genetic determinants of paraoxonase activity: FTO, SERPINA12, and ITGAL","volume":"54","author":"Kim","year":"2013","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib113","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.atherosclerosis.2004.05.029","article-title":"Roles of Sp1 and protein kinase C in regulation of human serum paraoxonase 1 (PON1) gene transcription in HepG2 cells","volume":"176","author":"Osaki","year":"2004","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib114","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1042\/CS20040187","article-title":"Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1","volume":"107","author":"Deakin","year":"2004","journal-title":"Clin. Sci."},{"key":"10.1016\/bs.acc.2024.04.003_bib115","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00228-013-1516-6","article-title":"Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients","volume":"69","author":"Kang","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/bs.acc.2024.04.003_bib116","first-page":"3","article-title":"Paraoxonases: an historical perspective","author":"Furlong","year":"2008","journal-title":"Paraoxonases: Their Role Dis. Dev. Xenobiotic Metab."},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib117","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1161\/01.ATV.0000096207.01487.36","article-title":"Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role for sterol regulatory element\u2013binding protein-2","volume":"23","author":"Deakin","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib118","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.metabol.2004.06.018","article-title":"Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene","volume":"54","author":"Ota","year":"2005","journal-title":"Metabolism"},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib119","first-page":"661","article-title":"Differential effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat","volume":"54","author":"Be\u0142towski","year":"2002","journal-title":"Pol. J. Pharmacol."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib120","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1124\/mol.63.4.945","article-title":"Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins","volume":"63","author":"Gou\u00e9dard","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/bs.acc.2024.04.003_bib121","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.plipres.2015.08.003","article-title":"Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials","volume":"60","author":"Ferretti","year":"2015","journal-title":"Prog. Lipid Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib122","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0014-5793(98)00064-7","article-title":"Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification","volume":"423","author":"Mackness","year":"1998","journal-title":"FEBS Lett."},{"issue":"14","key":"10.1016\/bs.acc.2024.04.003_bib123","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1177\/1535370216641786","article-title":"The common variant Q192R at the paraoxonase 1 (PON1) gene and its activity are responsible for a portion of the altered antioxidant status in type 2 diabetes","volume":"241","author":"Zargari","year":"2016","journal-title":"Exp. Biol. Med."},{"issue":"1-2","key":"10.1016\/bs.acc.2024.04.003_bib124","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jns.2014.01.006","article-title":"The salt stimulation property of serum paraoxonase (PON1) could be a valuable factor in evaluating the enzyme status in ischemic stroke: the role of activity-determined PON1 192Q\/R phenotypes","volume":"338","author":"Mahrooz","year":"2014","journal-title":"J. Neurological Sci."},{"key":"10.1016\/bs.acc.2024.04.003_bib125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cca.2018.05.037","article-title":"Paraoxonase 1 (PON1)-L55M among common variants in the coding region of the paraoxonase gene family may contribute to the glycemic control in type 2 diabetes","volume":"484","author":"Mahrooz","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib126","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-2275(20)31161-5","article-title":"Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations","volume":"42","author":"Leviev","year":"2001","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib127","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molmed.2009.11.003","article-title":"Epigenetics: molecular mechanisms and implications for disease","volume":"16","author":"Handel","year":"2010","journal-title":"Trends Mol. Med."},{"issue":"12","key":"10.1016\/bs.acc.2024.04.003_bib128","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.2337\/db09-1003","article-title":"Epigenetics: a molecular link between environmental factors and type 2 diabetes","volume":"58","author":"Ling","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib129","first-page":"143","article-title":"Cerivastatin modulates plasma paraoxonase\/arylesterase activity and oxidant-antioxidant balance in the rat","volume":"54","author":"Be\u0142towski","year":"2002","journal-title":"Pol. J. Pharmacol."},{"issue":"9","key":"10.1016\/bs.acc.2024.04.003_bib130","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nrcardio.2010.104","article-title":"Epigenetics and cardiovascular disease","volume":"7","author":"Ordov\u00e1s","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib131","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3390\/ijms21041203","article-title":"Early programming of adult systemic essential hypertension","volume":"21","author":"Guarner-Lans","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib132","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jnutbio.2013.09.016","article-title":"The regulation of hepatic Pon1 by a maternal high-fat diet is gender specific and may occur through promoter histone modifications in neonatal rats","volume":"25","author":"Strakovsky","year":"2014","journal-title":"J. Nutr. Biochem."},{"issue":"6a","key":"10.1016\/bs.acc.2024.04.003_bib133","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1582-4934.2010.01022.x","article-title":"Epigenetics in atherosclerosis and inflammation","volume":"14","author":"Wierda","year":"2010","journal-title":"J. Cell. Mol. Med."},{"issue":"10","key":"10.1016\/bs.acc.2024.04.003_bib134","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/14786419.2014.957699","article-title":"Atheroprotective potentials of curcuminoids against ginger extract in hypercholesterolaemic rabbits","volume":"29","author":"Elseweidy","year":"2015","journal-title":"Nat. Product. Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3892\/etm.2014.1717","article-title":"Piperine potentiates the hypocholesterolemic effect of curcumin in rats fed on a high fat diet","volume":"8","author":"Tu","year":"2014","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/bs.acc.2024.04.003_bib136","unstructured":"N. Nirmal, G.O. Praba, D. Velmurugan. Modeling Studies on Phospholipase A\u2082-Inhibitor Complexes. 2008."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib137","first-page":"513","article-title":"The use of curcumin in obstructive jaundice","volume":"5","author":"Karatepe","year":"2009","journal-title":"Arch. Med. Sci."},{"issue":"2","key":"10.1016\/bs.acc.2024.04.003_bib138","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.mce.2012.10.024","article-title":"Curcumin ameliorates diabetic nephropathy by inhibiting the activation of the SphK1-S1P signaling pathway","volume":"365","author":"Huang","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"issue":"8","key":"10.1016\/bs.acc.2024.04.003_bib139","doi-asserted-by":"crossref","first-page":"2406S","DOI":"10.1093\/jn\/132.8.2406S","article-title":"DNA methylation and atherosclerosis","volume":"132","author":"Dong","year":"2002","journal-title":"J. Nutr."},{"key":"10.1016\/bs.acc.2024.04.003_bib140","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s13105-014-0316-5","article-title":"Epigenetic patterns of two gene promoters (TNF-\u03b1 and PON) in stroke considering obesity condition and dietary intake","volume":"70","author":"G\u00f3mez-Uriz","year":"2014","journal-title":"J. Physiol. Biochem."},{"key":"10.1016\/bs.acc.2024.04.003_bib141","first-page":"416","article-title":"Arylesterase activity is associated with antioxidant intake and paraoxonase-1 (pon1) gene methylation in metabolic syndrome patients following an energy restricted diet","volume":"13","author":"de la Iglesia","year":"2014","journal-title":"EXCLI J."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib142","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/MOL.0000000000000687","article-title":"Epigenetics of paraoxonases","volume":"31","author":"Mahrooz","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib143","doi-asserted-by":"crossref","DOI":"10.1093\/eep\/dvv003","article-title":"PON1 as a model for integration of genetic, epigenetic, and expression data on candidate susceptibility genes","volume":"1","author":"Huen","year":"2015","journal-title":"Environ. Epigenetics"},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib144","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib145","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/CEJ.0000000000000645","article-title":"Role of microRNAs in the anticancer effects of the flavonoid luteolin: a systematic review","volume":"30","author":"Mishan","year":"2021","journal-title":"Eur. J. Cancer Prev."},{"issue":"12","key":"10.1016\/bs.acc.2024.04.003_bib146","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/gcc.22889","article-title":"Functional mechanisms of miR\u2010192 family in cancer","volume":"59","author":"Mishan","year":"2020","journal-title":"Genes, Chromosomes Cancer"},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib147","first-page":"267","article-title":"MicroRNAs may provide new strategies in the treatment and diagnosis of diabetic retinopathy: importance of VEGF","volume":"24","author":"Kordkheyli","year":"2021","journal-title":"Iran. J. Basic. Med. Sci."},{"key":"10.1016\/bs.acc.2024.04.003_bib148","doi-asserted-by":"crossref","DOI":"10.18502\/ijaai.v19i6.4930","article-title":"Epigallocatechin-3-gallate enhances the efficacy of microRNA-34a mimic and MiR-93 inhibitor co-transfection in prostate cancer cell line","author":"Mokhtari","year":"2020","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib149","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrd4279","article-title":"HDL-targeted therapies: progress, failures and future","volume":"13","author":"Kingwell","year":"2014","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2013.01.036","article-title":"A functional polymorphism of PON1 interferes with microRNA binding to increase the risk of ischemic stroke and carotid atherosclerosis","volume":"228","author":"Liu","year":"2013","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib151","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1159\/000491062","article-title":"Identification of prognostic value of Rs3735590 polymorphism in 3\u2032-untranslated region (3\u2032-UTR) of paraoxonase 1 (PON-1) in chronic obstructive pulmonary disease patients who received coronary artery bypass grafting (CABG)","volume":"47","author":"Lv","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib152","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1159\/000487565","article-title":"Functional SNP in the 3\u2032UTR of PON1 is associated with the risk of calcific aortic valve stenosis via MiR-616","volume":"45","author":"Wang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib153","doi-asserted-by":"crossref","first-page":"899","DOI":"10.5414\/CP202500","article-title":"Relationship of microRNA 616 gene polymorphism with prognosis of patients with premature coronary artery disease","volume":"54","author":"Zhang","year":"2016","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/bs.acc.2024.04.003_bib154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140958","article-title":"MiR-486 and miR-92a identified in circulating HDL discriminate between stable and vulnerable coronary artery disease patients","volume":"10","author":"Niculescu","year":"2015","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/bs.acc.2024.04.003_bib155","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.amjcard.2010.12.014","article-title":"Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome","volume":"107","author":"Casella-Filho","year":"2011","journal-title":"Am. J. Cardiol."},{"issue":"5","key":"10.1016\/bs.acc.2024.04.003_bib156","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0022-2275(20)30113-9","article-title":"Paraoxonase1-192 polymorphism modulates the effects of regular and acute exercise on paraoxonase1 activity","volume":"43","author":"Tom\u00e1s","year":"2002","journal-title":"J. lipid Res."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib157","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.atherosclerosis.2008.12.043","article-title":"The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study","volume":"206","author":"Zhang","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/bs.acc.2024.04.003_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-800141-7.00001-2","article-title":"HDL metabolism and atheroprotection: predictive value of lipid transfers","volume":"65","author":"Maranh\u00e3o","year":"2014","journal-title":"Adv. Clin. Chem."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib159","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pharmthera.2012.12.001","article-title":"Inflammation alters HDL composition and function: implications for HDL-raising therapies","volume":"137","author":"Marsche","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib160","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/jamacardio.2022.5143","article-title":"Higher high-density lipoprotein cholesterol\u2014good omen, bad omen, or not an omen at all","volume":"8","author":"Wilkins","year":"2023","journal-title":"JAMA Cardiol."},{"issue":"46","key":"10.1016\/bs.acc.2024.04.003_bib161","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1093\/eurheartj\/eht163","article-title":"Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting","volume":"34","author":"Angeloni","year":"2013","journal-title":"Eur. Heart J."},{"issue":"19","key":"10.1016\/bs.acc.2024.04.003_bib162","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.jacc.2016.08.038","article-title":"High-density lipoprotein cholesterol and cause-specific mortality in individuals without previous cardiovascular conditions: the CANHEART study","volume":"68","author":"Ko","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/bs.acc.2024.04.003_bib163","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamacardio.2022.0912","article-title":"Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations","volume":"7","author":"Liu","year":"2022","journal-title":"JAMA Cardiol."},{"issue":"9738","key":"10.1016\/bs.acc.2024.04.003_bib164","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"issue":"46","key":"10.1016\/bs.acc.2024.04.003_bib165","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1093\/eurheartj\/eht343","article-title":"High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality","volume":"34","author":"Silbernagel","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/bs.acc.2024.04.003_bib166","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"Bmj"},{"issue":"9841","key":"10.1016\/bs.acc.2024.04.003_bib167","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib168","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jacc.2014.11.019","article-title":"Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study","volume":"65","author":"Qi","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Supplement_1","key":"10.1016\/bs.acc.2024.04.003_bib169","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"Committee: ADAPP. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes\u20142022","volume":"45","author":"Committee ADAPP","year":"2022","journal-title":"Diabetes care"},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib170","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin. Chem."},{"issue":"10","key":"10.1016\/bs.acc.2024.04.003_bib171","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.bbalip.2018.08.002","article-title":"A critical appraisal of the measurement of serum \u2018cholesterol efflux capacity\u2019and its use as surrogate marker of risk of cardiovascular disease","volume":"1863","author":"Anastasius","year":"2018","journal-title":"Biochimica et. Biophysica Acta (BBA)-Molecular Cell Biol. Lipids"},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib172","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1161\/CIRCULATIONAHA.113.000962","article-title":"Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges","volume":"128","author":"Rosenson","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/bs.acc.2024.04.003_bib173","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.cca.2012.10.044","article-title":"Enzymatic assessment of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess HDL function","volume":"415","author":"Gugliucci","year":"2013","journal-title":"Clin. Chim. Acta"},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib174","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.2009.1346","article-title":"Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome","volume":"302","author":"Charakida","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/bs.acc.2024.04.003_bib175","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1194\/jlr.R800097-JLR200","article-title":"The HDL proteome: a marker\u2013and perhaps mediator\u2013of coronary artery disease","volume":"50","author":"Heinecke","year":"2009","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/bs.acc.2024.04.003_bib176","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.numecd.2020.12.026","article-title":"Improved risk assessment of coronary artery disease by substituting paraoxonase 1 activity for HDL-C: novel cardiometabolic biomarkers based on HDL functionality","volume":"31","author":"Mahrooz","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"8","key":"10.1016\/bs.acc.2024.04.003_bib177","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.numecd.2023.05.020","article-title":"Can HDL cholesterol be replaced by paraoxonase 1 activity in the prediction of severe coronary artery disease in patients with type 2 diabetes?","volume":"33","author":"Mahrooz","year":"2023","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib178","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41467-023-36258-w","article-title":"Quantifying PON1 on HDL with nanoparticle-gated electrokinetic membrane sensor for accurate cardiovascular risk assessment","volume":"14","author":"Kumar","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib179","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1373\/clinchem.2005.063412","article-title":"Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate","volume":"52","author":"Charlton-Menys","year":"2006","journal-title":"Clin. Chem."},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib180","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1194\/jlr.M600297-JLR200","article-title":"The 192R\/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux","volume":"47","author":"Gaidukov","year":"2006","journal-title":"J. Lipid Res."},{"issue":"9","key":"10.1016\/bs.acc.2024.04.003_bib181","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1161\/01.ATV.19.9.2214","article-title":"Human serum paraoxonase\/arylesterase\u2019s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein AI stabilizes activity","volume":"19","author":"Sorenson","year":"1999","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"35","key":"10.1016\/bs.acc.2024.04.003_bib182","doi-asserted-by":"crossref","first-page":"11843","DOI":"10.1021\/bi050862i","article-title":"High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I","volume":"44","author":"Gaidukov","year":"2005","journal-title":"Biochemistry"},{"issue":"3","key":"10.1016\/bs.acc.2024.04.003_bib183","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/j.1432-1033.1993.tb17620.x","article-title":"Identification of a distinct human high\u2010density lipoprotein subspecies defined by a lipoprotein\u2010associated protein, K\u201045: Identity of K\u201045 with paraoxonase","volume":"211","author":"Blatter","year":"1993","journal-title":"Eur. J. Biochem."},{"issue":"12","key":"10.1016\/bs.acc.2024.04.003_bib184","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1161\/ATVBAHA.109.194555","article-title":"HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein AI and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis","volume":"29","author":"Zerrad-Saadi","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1-3","key":"10.1016\/bs.acc.2024.04.003_bib185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0009-2797(93)90028-W","article-title":"Lipoproteins and hydrolysis of organophosphorus compounds","volume":"87","author":"Zech","year":"1993","journal-title":"Chem. Biol. Interact."},{"issue":"1","key":"10.1016\/bs.acc.2024.04.003_bib186","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00395-023-01004-2","article-title":"Identification of the specific molecular and functional signatures of pre-beta-HDL: relevance to cardiovascular disease","volume":"118","author":"Guillas","year":"2023","journal-title":"Basic. Res. Cardiol."},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib187","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.299.11.1265","article-title":"Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk","volume":"299","author":"Bhattacharyya","year":"2008","journal-title":"JAMA"},{"issue":"7-8","key":"10.1016\/bs.acc.2024.04.003_bib188","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0891-5849(98)00272-X","article-title":"Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants","volume":"26","author":"Aviram","year":"1999","journal-title":"Free. Radic. Biol. Med."},{"issue":"11","key":"10.1016\/bs.acc.2024.04.003_bib189","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1194\/jlr.M600297-JLR200","article-title":"The 192R\/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol effluxs","volume":"47","author":"Gaidukov","year":"2006","journal-title":"J. Lipid Res."},{"issue":"1-3","key":"10.1016\/bs.acc.2024.04.003_bib190","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cbi.2010.03.033","article-title":"Human PON1, a biomarker of risk of disease and exposure","volume":"187","author":"Furlong","year":"2010","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/bs.acc.2024.04.003_bib191","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.cbi.2016.08.007","article-title":"The effect of HDL-bound and free PON1 on copper-induced LDL oxidation","volume":"257","author":"Bayrak","year":"2016","journal-title":"Chem. Biol. Interact."},{"issue":"6","key":"10.1016\/bs.acc.2024.04.003_bib192","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/cts.12487","article-title":"Oral apolipoprotein A\u2010I mimetic D\u20104F lowers HDL\u2010inflammatory index in high\u2010risk patients: a first\u2010in\u2010human multiple\u2010dose, randomized controlled trial","volume":"10","author":"Dunbar","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/bs.acc.2024.04.003_bib193","series-title":"Paraoxonases in Inflammation, Infection, and Toxicology","first-page":"167","article-title":"The effect of HDL mimetic peptide 4F on PON1","author":"Vakili","year":"2010"}],"container-title":["Advances in Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242324000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0065242324000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T08:00:20Z","timestamp":1753430420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0065242324000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443297021"],"references-count":193,"URL":"https:\/\/doi.org\/10.1016\/bs.acc.2024.04.003","relation":{},"ISSN":["0065-2423"],"issn-type":[{"value":"0065-2423","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}